Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

• DOI: 10.1126/science.aao2774
• Publication Date: 2018-02-22T19:06:15Z
• Authors: Georgios Vlachogi...; Somaieh Hedayat; Alexandra Vatsiou; Yann Jamin; Javier Fernández-...; Khurum Khan; Andrea Lampis; Katherine Eason; Ian Huntingford; Rosemary Burke; Mihaela Rata; Dow-Mu Koh; Nina Tunariu; David Collins; Sanna Hulkki-Wilson; Chanthirika Ragulan; Inmaculada Spiteri; Sing Yu Moorcraft; Ian Chau; Sheela Rao; David Watkins; Nicos Fotiadis; Maria Bali; Mahnaz Darvish-Da...; Hazel Lote; Zakaria Eltahir; Elizabeth C. Smyth; Ruwaida Begum; Paul A. Clarke; Jens C. Hahne; Mitchell Dowsett; Johann de Bono; Paul Workman; Anguraj Sadanandam; Matteo Fassan; Owen J. Sansom; Suzanne Eccles; Naureen Starling; Chiara Braconi; Andrea Sottoriva; Simon P. Robinson; David Cunningham; Nicola Valeri
• Keywords: Organoid; Gastrointestinal cancer

Cancer organoids to model therapy response are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches used predict drug responses clinic. They generated a live organoid biobank patients with metastatic gastrointestinal cancer who had previously been enrolled phase I or II clinical trials. This allowed authors compare how actually responded Encouragingly, similar molecular profiles those of tumor, reinforcing their value as platform for screening development. Science , this issue p. 920